siRNA Therapeutics Patents: Who Leads, Where the Gaps Are 2026
- Two assignees account for all 22 records in scope, with Silence Therapeutics alone holding 21 — a concentration rarely seen even in tightly scoped therapeutic searches.
- Filings peaked in 2017 at 13 and have gone flat since, with the 2022 midpoint at zero — a signal that the core GalNAc conjugate claim space was staked out early and the trend line has not recovered since publication catches up with the 18-month lag.
- 86.4% of the 22 records sit in A61K and 72.7% in C12N, while C07H (sugars & nucleic acids) covers only 13.6% and C12Q barely 4.5% — the chemistry-of-modification and diagnostic-adjacent branches are thin by comparison.
What this landscape covers
This review scans records published between 2015 and 2026 that combine core siRNA therapeutic language with claim-level terms such as GalNAc conjugate, off-target silencing, chemical modification pattern, durability of knockdown and extrahepatic delivery, restricted to IPC classes C12N15, A61K31 and A61K47. The scope is narrow by design: it isolates the conjugate-chemistry and delivery layer of siRNA patenting rather than the whole RNAi literature.
Within that scope the dataset is small — 22 records total — and dominated by a single assignee's trivalent GalNAc glycoconjugate family. That makes the landscape less useful as a market-share signal and more useful as a freedom-to-operate check on one well-cited claim family and the receiving offices where it has been pursued.
Filing trend and technology composition
Publication counts by year and IPC subclass, drawn from the 22 records in scope.
Filings rose sharply then went flat
Filings climbed to a peak of 13 in 2017, then declined; the 2022 midpoint sits at zero and 2026 (partial) shows none yet. Because publication typically lags filing by around 18 months, the most recent years understate true filing activity, but the multi-year plateau at zero before that lag window suggests the core claim territory here was largely staked out in the 2017 filing wave rather than being actively re-contested since.
Medicinal preparations and genetic engineering dominate
A61K (medicinal preparations) appears in 86.4% of the 22 records and C12N (microorganisms & genetic engineering) in 72.7%, consistent with a corpus centred on therapeutic conjugate compounds. A61P (therapeutic activity) reaches 68.2%. C07H (sugars & nucleic acids, 13.6%) and C12Q (enzyme/DNA measurement, 4.5%) are comparatively undercovered, which is notable given how central sugar-conjugate chemistry is to GalNAc delivery.
Shares are the percentage of the 22 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on siRNA Therapeutics with Eureka
This page is one run against one query. Ask Eureka your own question about sirna therapeutics and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited record in this scope
Nucleic acid linked to a trivalent glycoconjugate (US10913945B2)
The compound comprises a modified saccharide moiety conjugated to a nucleic acid, useful in medicine for RNA interference therapy or for research and diagnostic purposes, in particular for treating liver disease.Filed by Silence Therapeutics GmbH; granted 2021-02-09.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2017174657A1 | Nucleic acid linked to a trivalent glycoconjugate | 116 |
| 2 | US20190119676A1 | Nucleic acid linked to a trivalent glycoconjugate | 7 |
| 3 | US20210079397A1 | Nucleic acid linked to a trivalent glycoconjugate | 3 |
| 4 | US10913945B2 | Nucleic acid linked to a trivalent glycoconjugate | 2 |
| 5 | WO2018185210A1 | Further novel oligonucleotide-ligand conjugates | 1 |
| 6 | US20210087570A1 | Further novel oligonucleotide-ligand conjugates | 1 |
Citation counts reflect influence within this searched corpus and favour older filings; treat them as a signal of prior influence, not current commercial weight.
Publication numbers are shown where the record carries one (6 of 6 rows); clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the data means for filing strategy
Three findings shape how a team should read this corpus before drafting or licensing around siRNA conjugate chemistry.
This is a two-player field, not a market
The entire ranked set of 22 records in scope sits with two assignees, and the leader alone accounts for 21 of them. Any freedom-to-operate question in this exact claim space reduces almost entirely to one company's family.
The filing wave already happened
Activity peaked in 2017 and had gone flat by the 2022 midpoint, with no filings yet recorded for 2026. Recent-year momentum by assignee shows 0% activity from both parties in the latest year, including a -100% YoY drop for the smaller filer.
Sugar-conjugate chemistry is thin relative to formulation claims
Medicinal-preparation claims (A61K, 86.4%) and genetic-engineering claims (C12N, 72.7%) dominate, while the sugars-and-nucleic-acids class C07H covers only 13.6% of the 22 records — a gap given that GalNAc conjugation is itself a sugar-chemistry problem.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to sirna therapeutics, with the prior art for and against each one.
Who holds the claims
Two assignees cover the entire ranked set. One holds the great majority of the family; the other's activity has already stopped.
Silence Therapeutics-linked entity holds the core family
This assignee accounts for 21 of the 22 records, including the most-cited trivalent GalNAc glycoconjugate filings. Recent-year momentum for this assignee is flat at 0, consistent with the broader plateau in the trend.
Suzhou-based filer shows a sharp pullback
The second assignee's activity fell -100% year-on-year and now stands at 0 in the latest year, suggesting either a strategic pause or that its filed claims in this narrow scope are already complete.
No long tail exists in this scope
Unlike broader therapeutic landscapes, this search returns no third, fourth or fifth entrant — the entire ranking the data endpoint returns is these two names, covering 100.0% of the 22 records.
| Assignee | Recent year | YoY |
|---|---|---|
| Silence Therapeutics GmbH | 0 | — |
| Suzhou Sanjun Pharmaceutical Technology Co., Ltd. | 0 | -100% |
How to use this landscape
The next steps depend on whether the goal is freedom-to-operate, licensing, or identifying open claim territory.
Check freedom-to-operate against the leader's family
With one assignee holding 21 of 22 records, any conjugate-chemistry programme in this exact scope should start with a claim-by-claim read of that family, not a broad landscape survey.
Explore claim charts in EurekaProbe the thin classes before drafting
C07H and C12Q coverage is low relative to A61K and C12N. A first claim anchored in sugar-linker variation or knockdown-durability assay methods faces less dense prior art in this scope.
Run a white-space search in EurekaWatch for the second filer's next move
A -100% YoY drop does not necessarily mean exit; it may mean the smaller filer is re-scoping. Track new publications from this assignee for early signal.
Set up assignee monitoring in EurekaCommon questions on siRNA therapeutics patents
Within this scope of 22 records, one assignee linked to Silence Therapeutics holds 21 of them, including the most-cited family covering trivalent glycoconjugate-linked nucleic acids. A second, smaller filer based in Suzhou accounts for the remainder. Together the two cover 100.0% of the records returned by this search, so there is no meaningful long tail of additional filers in this exact claim space.
No, not in this scope. Filings peaked at 13 in 2017 and had fallen to zero by the 2022 midpoint, with none recorded yet for 2026. Because publication lags filing by roughly 18 months, the very latest years will always look thinner than they eventually turn out to be, but the multi-year plateau before that lag window suggests filing activity in this narrow GalNAc-conjugate space has genuinely slowed rather than simply awaiting publication.
US10913945B2 claims a compound comprising a modified saccharide moiety conjugated to a nucleic acid, useful for RNA interference therapy and specifically for treating liver disease. It sits within a family of related filings from the same assignee (Silence Therapeutics GmbH) covering trivalent glycoconjugate-linked nucleic acids, and it is the most-cited record in this dataset by a wide margin. Anyone designing a GalNAc-conjugated siRNA compound for hepatic delivery should review this claim family closely before finalising a chemical structure.
Relative to the dense coverage of medicinal-preparation claims (A61K, 86.4% of the 22 records) and genetic-engineering claims (C12N, 72.7%), the sugars-and-nucleic-acids class C07H covers only 13.6% and assay-related C12Q just 4.5%. That points to comparatively open territory in sugar-linker chemistry variants, extrahepatic delivery mechanisms, and durability-of-knockdown measurement methods, though the small total record count (22) means any white-space read here should be treated as directional rather than definitive.
Extremely concentrated within this specific search scope: two assignees account for all 22 records returned, with one holding 21 of them. This is not typical of siRNA patenting broadly — it reflects the narrow combination of GalNAc conjugate, off-target silencing and chemical modification terms used to build this dataset. A broader search on RNAi therapeutics generally would surface many more assignees; this landscape is best read as a close-up on one heavily claimed conjugate chemistry corner of that field.
Research siRNA Therapeutics in depth with Eureka
Go past this page: query the whole sirna therapeutics corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.